Immune; Immunotherapy; Toxicity; Cancer; related adverse events; Immunologic Factors; Humans; Immunotherapy/adverse effects; Drug-Related Side Effects and Adverse Reactions; Neoplasms/therapy; Immune-relate adverse events; Neoplasms; Medicine (all)
Abstract :
[en] Immunotherapy has revolutionized cancer management in recent years and is affecting more and more patients. Immunotherapy side effects are specific, immune-related, and their early recognition and management are essential. Here we describe the main adverse effects of immunotherapy and their general principles of management. [fr] L’immunothérapie a révolutionné la prise en charge des cancers ces dernières années et concerne de plus en plus de patients. Les manifestations indésirables de l’immunothérapie sont spécifiques, de type dysimmunitaire, et leur reconnaissance et prise en charge précoces sont primordiales. Dans cet article, nous décrivons les principaux effets secondaires de l’immunothérapie et leurs principes généraux de prise en charge.
Disciplines :
Oncology
Author, co-author :
Freres, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Poncin, Aurélie ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Lecocq, Marie ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Language :
French
Title :
Les manifestations indésirables liées à l’immunothérapie.
Disis ML. Mechanism of action of immunotherapy. Semin Oncol 2014;41:S3-13.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019;381:1535-46.
Absil G, Damsin T, Lebas E, et al. Le mélanome: le trajet de soins du patient. Du diagnostic au traitement. Rev Med Liege 2021;76:489-95.
Eggermont AM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018;378:1789-801.
Sibille A, Corhay JL, Vaillant F, et al. Traitements ciblés et cancer bronchique non à petites cellules: le point en 2021. Rev Med Liege 2021;76:458-64.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30.
Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015;26:2375-91.
Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. Ann Oncol 2016;27:559-74.
Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 2018;4:1721-8.
Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma. J Clin Oncol 2017;35:785-92.
Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 2014;71:161-9.
Haanen JB, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:119-42.
Tsung I, Dolan R, Lao CD, et al. Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. Aliment Pharmacol Ther 2019;50:800-8.
Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens a systematic review and meta-analysis. JAMA Oncol 2018;4:173-82.
Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: Results from the phase i KEYNOTE-001 study. J Clin Oncol 2019;37:2518-27.
Fellner A, Makranz C, Lotem M, et al. Neurologic complications of immune checkpoint inhibitors. J Neurooncol 2018;137:601-9.
Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749-55.
Zhang L, Zlotoff DA, Awadalla M, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation 2020;141:2031-4.
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 2018;36:1714-68.
Eggermont AM, Kicinski M, Blank CU, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol 2020;6:519-27.
